Susanne Diehl

Company: Novartis AG

Job title: Vice President, Global Program Head Immunology

Seminars:

Panel Discussion: Evaluating the Future of Autologous & Allogeneic Therapies 11:30 am

Evaluating the autologous and allogeneic cell therapy space Identify the optimal approach to maximize therapeutic efficacy Consider patient safety by addressing challenges related to rejection and adverse immune responses in both autologous and allogeneic therapies Evaluate if autologous or allogeneic therapies are best for future autoimmune therapy personalizationRead more

day: Conference Day Two Pink Track

Panel Discussion: Utilizing Biomarkers to Sustain Durable Responses in Autoimmune Therapies 1:40 pm

Identifying biomarker differences across indications and modalities Harness specific biomarkers to effectively identify patient response, manage patient safety and enhance patient selection Explore the use of biomarkers to determine optimal timing for re-dosing and sustaining efficacyRead more

day: Conference Day One Teal Track P2